Cargando…
Impacts on product quality attributes of monoclonal antibodies produced in CHO cell bioreactor cultures during intentional mycoplasma contamination events
A mycoplasma contamination event in a biomanufacturing facility can result in costly cleanups and potential drug shortages. Mycoplasma may survive in mammalian cell cultures with only subtle changes to the culture and penetrate the standard 0.2‐µm filters used in the clarification of harvested cell...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7496122/ https://www.ncbi.nlm.nih.gov/pubmed/32436993 http://dx.doi.org/10.1002/bit.27436 |
_version_ | 1783583028048560128 |
---|---|
author | Fratz‐Berilla, Erica J. Angart, Phillip Graham, Ryan J. Powers, David N. Mohammad, Adil Kohnhorst, Casey Faison, Talia Velugula‐Yellela, Sai Rashmika Trunfio, Nicholas Agarabi, Cyrus |
author_facet | Fratz‐Berilla, Erica J. Angart, Phillip Graham, Ryan J. Powers, David N. Mohammad, Adil Kohnhorst, Casey Faison, Talia Velugula‐Yellela, Sai Rashmika Trunfio, Nicholas Agarabi, Cyrus |
author_sort | Fratz‐Berilla, Erica J. |
collection | PubMed |
description | A mycoplasma contamination event in a biomanufacturing facility can result in costly cleanups and potential drug shortages. Mycoplasma may survive in mammalian cell cultures with only subtle changes to the culture and penetrate the standard 0.2‐µm filters used in the clarification of harvested cell culture fluid. Previously, we reported a study regarding the ability of Mycoplasma arginini to persist in a single‐use, perfusion rocking bioreactor system containing a Chinese hamster ovary (CHO) DG44 cell line expressing a model monoclonal immunoglobulin G 1 (IgG1) antibody. Our previous work showed that M. arginini affects CHO cell growth profile, viability, nutrient consumption, oxygen use, and waste production at varying timepoints after M. arginini introduction to the culture. Careful evaluation of certain identified process parameters over time may be used to indicate mycoplasma contamination in CHO cell cultures in a bioreactor before detection from a traditional method. In this report, we studied the changes in the IgG1 product quality produced by CHO cells considered to be induced by the M. arginini contamination events. We observed changes in critical quality attributes correlated with the duration of contamination, including increased acidic charge variants and high mannose species, which were further modeled using principal component analysis to explore the relationships among M. arginini contamination, CHO cell growth and metabolites, and IgG1 product quality attributes. Finally, partial least square models using NIR spectral data were used to establish predictions of high levels (≥10(4) colony‐forming unit [CFU/ml]) of M. arginini contamination, but prediction of levels below 10(4) CFU/ml were not reliable. Contamination of CHO cells with M. arginini resulted in significant reduction of antibody product quality, highlighting the importance of rapid microbiological testing and mycoplasma testing during particularly long upstream bioprocesses to ensure product safety and quality. |
format | Online Article Text |
id | pubmed-7496122 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-74961222020-09-25 Impacts on product quality attributes of monoclonal antibodies produced in CHO cell bioreactor cultures during intentional mycoplasma contamination events Fratz‐Berilla, Erica J. Angart, Phillip Graham, Ryan J. Powers, David N. Mohammad, Adil Kohnhorst, Casey Faison, Talia Velugula‐Yellela, Sai Rashmika Trunfio, Nicholas Agarabi, Cyrus Biotechnol Bioeng ARTICLES A mycoplasma contamination event in a biomanufacturing facility can result in costly cleanups and potential drug shortages. Mycoplasma may survive in mammalian cell cultures with only subtle changes to the culture and penetrate the standard 0.2‐µm filters used in the clarification of harvested cell culture fluid. Previously, we reported a study regarding the ability of Mycoplasma arginini to persist in a single‐use, perfusion rocking bioreactor system containing a Chinese hamster ovary (CHO) DG44 cell line expressing a model monoclonal immunoglobulin G 1 (IgG1) antibody. Our previous work showed that M. arginini affects CHO cell growth profile, viability, nutrient consumption, oxygen use, and waste production at varying timepoints after M. arginini introduction to the culture. Careful evaluation of certain identified process parameters over time may be used to indicate mycoplasma contamination in CHO cell cultures in a bioreactor before detection from a traditional method. In this report, we studied the changes in the IgG1 product quality produced by CHO cells considered to be induced by the M. arginini contamination events. We observed changes in critical quality attributes correlated with the duration of contamination, including increased acidic charge variants and high mannose species, which were further modeled using principal component analysis to explore the relationships among M. arginini contamination, CHO cell growth and metabolites, and IgG1 product quality attributes. Finally, partial least square models using NIR spectral data were used to establish predictions of high levels (≥10(4) colony‐forming unit [CFU/ml]) of M. arginini contamination, but prediction of levels below 10(4) CFU/ml were not reliable. Contamination of CHO cells with M. arginini resulted in significant reduction of antibody product quality, highlighting the importance of rapid microbiological testing and mycoplasma testing during particularly long upstream bioprocesses to ensure product safety and quality. John Wiley and Sons Inc. 2020-06-04 2020-09 /pmc/articles/PMC7496122/ /pubmed/32436993 http://dx.doi.org/10.1002/bit.27436 Text en © 2020 The Authors. Biotechnology and Bioengineering published by Wiley Periodicals LLC This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | ARTICLES Fratz‐Berilla, Erica J. Angart, Phillip Graham, Ryan J. Powers, David N. Mohammad, Adil Kohnhorst, Casey Faison, Talia Velugula‐Yellela, Sai Rashmika Trunfio, Nicholas Agarabi, Cyrus Impacts on product quality attributes of monoclonal antibodies produced in CHO cell bioreactor cultures during intentional mycoplasma contamination events |
title | Impacts on product quality attributes of monoclonal antibodies produced in CHO cell bioreactor cultures during intentional mycoplasma contamination events |
title_full | Impacts on product quality attributes of monoclonal antibodies produced in CHO cell bioreactor cultures during intentional mycoplasma contamination events |
title_fullStr | Impacts on product quality attributes of monoclonal antibodies produced in CHO cell bioreactor cultures during intentional mycoplasma contamination events |
title_full_unstemmed | Impacts on product quality attributes of monoclonal antibodies produced in CHO cell bioreactor cultures during intentional mycoplasma contamination events |
title_short | Impacts on product quality attributes of monoclonal antibodies produced in CHO cell bioreactor cultures during intentional mycoplasma contamination events |
title_sort | impacts on product quality attributes of monoclonal antibodies produced in cho cell bioreactor cultures during intentional mycoplasma contamination events |
topic | ARTICLES |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7496122/ https://www.ncbi.nlm.nih.gov/pubmed/32436993 http://dx.doi.org/10.1002/bit.27436 |
work_keys_str_mv | AT fratzberillaericaj impactsonproductqualityattributesofmonoclonalantibodiesproducedinchocellbioreactorculturesduringintentionalmycoplasmacontaminationevents AT angartphillip impactsonproductqualityattributesofmonoclonalantibodiesproducedinchocellbioreactorculturesduringintentionalmycoplasmacontaminationevents AT grahamryanj impactsonproductqualityattributesofmonoclonalantibodiesproducedinchocellbioreactorculturesduringintentionalmycoplasmacontaminationevents AT powersdavidn impactsonproductqualityattributesofmonoclonalantibodiesproducedinchocellbioreactorculturesduringintentionalmycoplasmacontaminationevents AT mohammadadil impactsonproductqualityattributesofmonoclonalantibodiesproducedinchocellbioreactorculturesduringintentionalmycoplasmacontaminationevents AT kohnhorstcasey impactsonproductqualityattributesofmonoclonalantibodiesproducedinchocellbioreactorculturesduringintentionalmycoplasmacontaminationevents AT faisontalia impactsonproductqualityattributesofmonoclonalantibodiesproducedinchocellbioreactorculturesduringintentionalmycoplasmacontaminationevents AT velugulayellelasairashmika impactsonproductqualityattributesofmonoclonalantibodiesproducedinchocellbioreactorculturesduringintentionalmycoplasmacontaminationevents AT trunfionicholas impactsonproductqualityattributesofmonoclonalantibodiesproducedinchocellbioreactorculturesduringintentionalmycoplasmacontaminationevents AT agarabicyrus impactsonproductqualityattributesofmonoclonalantibodiesproducedinchocellbioreactorculturesduringintentionalmycoplasmacontaminationevents |